Navigation

TA75 Hepatitis C - pegylated interferons, ribavirin and alfa interferon: guidance

This guidance has been partially updated by Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (NICE technology appraisal guidance 200) and Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people (NICE technology appraisal guidance 300.   

This guidance is a review and extension of Technology Appraisal Guidance No. 14 issued in October 2000. The Institute reviews each piece of guidance it issues.

The review and re-appraisal has resulted in an extension to the guidance; combination therapy with pegylated interferon alfa and ribavirin is recommended for the treatment of people aged 18 years and over with moderate to severe chronic hepatitis C.

This page was last updated: 27 November 2013

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.